Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
0 competitors in KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting
View Full LandscapeTarget Indication
KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting
Clinical Trial
NCT07232875Last updated: 7/21/2026
No patent data available. Pre-approval drugs may not have Orange Book listings.
Non-Small-Cell Lung Cancer
Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer
Primary Hypercholesterolemia
HER2-positive Breast Cancer
Severe Aplastic Anemia